Jesús Sierra

Featured in: Favicon

elpais.com Favicon

apnews.com Favicon

elnuevoherald.com Favicon

tucson.com Favicon

jotdown.es Favicon

unirioja.es Favicon

zyzzyva.org Favicon

biorxiv.org + 6 more

Articles

Re: [177Lu]Lu-PSMA-617 plus Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer (ENZA-p): An Open-label, Multicentre, Randomised, Phase 2 Trial

2 months ago | europeanurology.com | Juan Rivas |Jesús Sierra

Emmett L, Subramaniam S, Crumbaker M, et alLancet Oncol 2024;25:563–71Experts’ summary:The ENZA-p trial assessed the efficacy and safety of combining [177Lu]Lu-PSMA-617 with enzalutamide in comparison to enzalutamide alone in patients with metastatic castration-resistant prostate cancer (mCRPC) and at least two risk factors for early progression. This open-label, randomized, phase 2 trial enrolled 162 patients across 15 centers in Australia.

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →